If a woman can not take alendronate, ryzedronat ...

Technology assessment, TA160 - Released: January 2011

or not, in postmenopausal women suffering from osteoporosis, offered one of these drugs to prevent bone fractures depends on her age, her bone density and how many factors risk for fracture and indicators of fragile bones she has. In principle, alendronate is recommended as a possible treatment for preventing fractures in postmenopausal women who were diagnosed osteoporosis but no fracture. If a woman can not take alendronate, and ryzedronat etidronat recommended under certain circumstances possible alternative treatments to prevent fractures. If a woman can not take alendronate or ryzedronat or etidronat, the strontium ranelate is recommended under certain circumstances as a possible alternative treatment to prevent fractures. Raloksifen not recommended for treatment of prevention of fractures in postmenopausal women suffering from osteoporosis, which had no cracks. The guide says that women who are 75 years and older do not need bone scans to diagnose their osteoporosis. NICE has published updated final recommendations for the prevention of fractures after strontium ranelate reapply for the prevention and treatment of fragility fractures in postmenopausal women. According to the Court of Appeal decision on technology assessment of drugs for the prevention and treatment of fragility fractures in postmenopausal women, NICE asked the manufacturer of strontium ranelate to submit additional evidence. After reviewing the additional evidence strontium ranelate and independent examination of the evidence very carefully, a new independent evaluation committee came to the same conclusions as the lasix 15 mg original of the Evaluation Committee, and therefore strontium ranelate recommendations remain unchanged, published first. Consultants, he had the opportunity to appeal, but no calls were received. NICE guide to the use of alendronate, etidronat, ryzedronat, raloxifene, strontium ranelate and teriparatide for the prevention and treatment of fragility fractures in postmenopausal women is unchanged. .